Cargando…
SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
Background: Testosterone and its metabolite estradiol are essential factors in bone metabolism, and hypogonadism is an established risk factor for osteoporosis. Material and Methods: In a registry study of otherwise unselected men with hypogonadism in a urological office, 102 of 805 patients (13%) h...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551956/ http://dx.doi.org/10.1210/js.2019-SAT-533 |